Benzinga | Jul 1, 2021 04:18PM EDT

BioCryst Pharmaceuticals Announces ORLADEYO Data To Be Presented At European Academy Of Allergy And Clinical Immunology Hybrid Congress

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) today announced multiple upcoming data presentations at the European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress from July 10-12, 2021.

* Durable Reduction in Hereditary Angioedema (HAE) Attack Rates with Berotralstat Over 24 Months: Results from the Phase 3 APeX-2 Study, Oral Session: The Wide New Allergy World, Abstract #170: Monday, July 12, 2021, 14:15 - 15:45 CET

* Berotralstat Demonstrates Consistently Low Attack Rates in Adolescent Patients: Subgroup Analysis from APeX-S, ePoster Discussion: Advances in Urticaria, Angioedema and Skin Allergy, Abstract #336, Sunday, July 11, 2021, 12:30 - 13:30 CET

* Reduction in On-Demand Medications in Patients with Hereditary Angioedema (HAE) Treated with Berotralstat, ePoster Discussion: Advances in urticaria, angioedema and skin allergy, Abstract #250, Sunday, July 11, 2021, 12:30 - 13:30 CET

ePosters

* Berotralstat Demonstrates Consistently Low HAE Attack Rates During COVID-19: Subgroup Analysis from the APeX-S trial, ePoster Dermatology, Abstract #166

* Berotralstat Reduces Hereditary Angioedema Attack Rates Regardless of Previous Prophylaxis, ePoster Dermatology, Abstract #199

* Challenges of Discontinuing Prophylactic Androgens for Hereditary Angioedema, ePoster Dermatology, Abstract #210